Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

ClinicalTrials.gov ID: NCT02093026

Public ClinicalTrials.gov record NCT02093026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of participants who were previously randomized into studies WA16291 (NCT02693210) or WA17043/U2644g (NCT00074438). The study permits multiple re-treatments until the protocol-defined end-of-treatment date (31 December 2011). Participants will then enter a safety follow-up (SFU) period of at least 48 weeks. This will provide at least 7 years follow-up data on all participants initially randomized into WA16291 or WA17043/U2644g. Approximately 600 participants will potentially be eligible to enter this open label extension study from their respective feeder studies.

Study identification

NCT ID
NCT02093026
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
465 participants

Conditions and interventions

Eligibility (public fields only)

Age range
21 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2002
Primary completion
Nov 30, 2012
Completion
Nov 30, 2012
Last update posted
Mar 12, 2017

2002 – 2012

United States locations

U.S. sites
42
U.S. states
24
U.S. cities
39
Facility City State ZIP Site status
Not listed Birmingham Alabama 35294
Not listed Peoria Arizona 85381
Not listed Little Rock Arkansas 72205
Not listed La Jolla California 92037
Not listed Long Beach California 92813
Not listed Rancho Mirage California 92270
Not listed San Diego California 92108
Not listed Colorado Springs Colorado 80920
Not listed Aventura Florida 33180
Not listed Boca Raton Florida 33486
Not listed Fort Lauderdale Florida 33334
Not listed Largo Florida 33773
Not listed South Miami Florida 33143
Not listed Boise Idaho 83702
Not listed Chicago Illinois 60611
Not listed Chicago Illinois 60637
Not listed Indianapolis Indiana 46202-5149
Not listed Indianapolis Indiana 46260
Not listed Boston Massachusetts 02215
Not listed Minneapolis Minnesota 55416
Not listed St Louis Missouri 63141
Not listed Lebanon New Hampshire 03756
Not listed Voorhees Township New Jersey 08043
Not listed Great Neck New York 11021
Not listed Plainview New York 11803
Not listed Rochester New York 14618
Not listed Smithtown New York 11787
Not listed Greenville North Carolina 27834
Not listed Winston-Salem North Carolina 27157
Not listed Beachwood Ohio 44122
Not listed Dayton Ohio 45402
Not listed Mayfield Ohio 44143
Not listed Tulsa Oklahoma 74104
Not listed Tulsa Oklahoma 74135
Not listed Portland Oregon 97239
Not listed Duncansville Pennsylvania 16635
Not listed Dallas Texas 75231
Not listed Houston Texas 77074
Not listed Salt Lake City Utah 84132
Not listed Seattle Washington 98104
Not listed Glendale Wisconsin 53217
Not listed Wausau Wisconsin 54401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02093026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 12, 2017 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02093026 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →